Zacks Research Has Negative Outlook for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Research analysts at Zacks Research lowered their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a research note issued to investors on Tuesday, March 24th. Zacks Research analyst J. Vandermosten now anticipates that the biopharmaceutical company will post earnings per share of ($1.40) for the year, down from their previous estimate of ($1.07). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.65) EPS.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01).

Other equities analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Achieve Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

Achieve Life Sciences Stock Down 8.3%

ACHV opened at $2.65 on Friday. The company has a market capitalization of $141.06 million, a P/E ratio of -2.04 and a beta of 1.81. Achieve Life Sciences has a fifty-two week low of $1.84 and a fifty-two week high of $6.03. The stock has a fifty day moving average of $4.31 and a 200-day moving average of $4.30. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.14 and a current ratio of 4.39.

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACHV. ADAR1 Capital Management LLC lifted its holdings in shares of Achieve Life Sciences by 10.7% in the third quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 4,627 shares in the last quarter. Bank of America Corp DE grew its holdings in Achieve Life Sciences by 39.9% during the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 9,617 shares in the last quarter. Robertson Stephens Wealth Management LLC raised its position in Achieve Life Sciences by 100.0% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 10,000 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Achieve Life Sciences in the 1st quarter valued at $32,000. Finally, Manchester Financial Inc. lifted its stake in Achieve Life Sciences by 26.6% during the 4th quarter. Manchester Financial Inc. now owns 59,084 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 12,410 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Key Headlines Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.